PHARMELLE: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
PHARMELLE
Largest movements
- Cash -€11,149
down €11,149 (-22.9%), from €48,787 to €37,638
mainly Contributions, distributions and other (-€38,125) and Receivables within one year (-€8,062)
- Receivables within one year +€8,062
up €8,062 (+806%), from €1,000 to €9,062
of which Trade receivables: +€8,168
- Tangible fixed assets +€1,128
up €1,128 (+265%), from €425 to €1,553
- Other debts +€33,227
up €33,227 (+801%), from €4,146 to €37,373
- Profit (loss) carried forward -€30,717
down €30,717 (-80.6%), from €38,125 to €7,408
- Tax, wage and social debts -€4,374
down €4,374 (-83.5%), from €5,238 to €864
- Financial charges +€1,217
up €1,217 (+364%), from €334 to €1,551
- Gross operating margin -€776
down €776 (-5.5%), from €14,184 to €13,408
- Taxes -€704
down €704 (-20.7%), from €3,399 to €2,694
- Other operating charges +€415
up €415 (+48.1%), from €864 to €1,280
- Depreciation +€197
up €197 (+70.8%), from €278 to €474
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €50,587 | €48,646 | -€1,941 | -3.8% |
| Fixed assets | 21/28 | €425 | €1,553 | +€1,128 | +265% |
| Tangible fixed assets | 22/27 | €425 | €1,553 | +€1,128 | +265% |
| Furniture and vehicles | 24 | €425 | €1,553 | +€1,128 | +265% |
| Current assets | 29/58 | €50,162 | €47,093 | -€3,069 | -6.1% |
| Amounts receivable within one year | 40/41 | €1,000 | €9,062 | +€8,062 | +806% |
| Trade receivables | 40 | €0 | €8,168 | +€8,168 | |
| Other amounts receivable | 41 | €1,000 | €895 | -€105 | -10.5% |
| Cash at bank and in hand | 54/58 | €48,787 | €37,638 | -€11,149 | -22.9% |
| Deferred charges and accrued income | 490/1 | €375 | €392 | +€18 | +4.7% |
| Total equity and liabilities | 10/49 | €50,587 | €48,646 | -€1,941 | -3.8% |
| Equity | 10/15 | €41,125 | €10,408 | -€30,717 | -74.7% |
| Contributions | 10/11 | €3,000 | €3,000 | = | 0.0% |
| Profit (loss) carried forward | 14 | €38,125 | €7,408 | -€30,717 | -80.6% |
| Amounts payable | 17/49 | €9,462 | €38,238 | +€28,776 | +304% |
| Amounts payable within one year | 42/48 | €9,462 | €38,238 | +€28,776 | +304% |
| Trade debts | 44 | €77 | €0 | -€77 | -100% |
| Suppliers | 440/4 | €77 | €0 | -€77 | -100% |
| Taxes, remuneration and social security | 45 | €5,238 | €864 | -€4,374 | -83.5% |
| Taxes | 450/3 | €5,238 | €864 | -€4,374 | -83.5% |
| Other amounts payable | 47/48 | €4,146 | €37,373 | +€33,227 | +801% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €278 | €474 | +€197 | +70.8% |
| Other operating charges | 640/8 | €864 | €1,280 | +€415 | +48.1% |
| Gross operating margin | 9900 | €14,184 | €13,408 | -€776 | -5.5% |
| Operating profit (loss) | 9901 | €13,042 | €11,654 | -€1,388 | -10.6% |
| Financial charges | 65/66B | €334 | €1,551 | +€1,217 | +364% |
| Recurring financial charges | 65 | €334 | €1,551 | +€1,217 | +364% |
| Profit (loss) for the period before taxes | 9903 | €12,708 | €10,103 | -€2,605 | -20.5% |
| Income taxes | 67/77 | €3,399 | €2,694 | -€704 | -20.7% |
| Profit (loss) for the period | 9904 | €9,309 | €7,408 | -€1,900 | -20.4% |
| Profit (loss) for the period to be appropriated | 9905 | €9,309 | €7,408 | -€1,900 | -20.4% |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 15 October 2026 via checked.be.